High-dose sequential chemotherapy and rituximab (R-HDS) supported by autologous stem cell transplantation (ASCT) in patients (pts) with systemic B-cell lymphoma with CNS involvement (SCNSL) at diagnosis or relapse: Interim analysis of feasibility and activity of a phase II trial.

医学 美罗华 内科学 阿糖胞苷 自体干细胞移植 胃肠病学 中性粒细胞减少症 依托泊苷 环磷酰胺 噻替帕 化疗 肿瘤科 移植 外科 淋巴瘤
作者
Andrea Assanelli,K. Patti,S Cortelazzo,Luigi Rigacci,Liliana Devizzi,Marco Foppoli,Antonino Mulè,Fabio Ciceri,Corrado Tarella,Andrés J.M. Ferreri
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:28 (15_suppl): 8081-8081 被引量:1
标识
DOI:10.1200/jco.2010.28.15_suppl.8081
摘要

8081 Background: High-dose (HD) chemotherapy supported by ASCT exhibited promising results in a few, small retrospective series of SCNSL. Herein we report the interim analysis of a phase II trial (ClinicalTrials.gov #NCT00801216) addressing a new R-HDS combination with ASCT in these poor-prognosis pts. Methods: Pts (≤65 ys old; ECOG PS 0-3) with SCNSL at diagnosis or relapse were treated with 2 c. of HD-methotrexate + HD-cytarabine (induction); 3 sequential c. of HD-cyclophosphamide, HD-cytarabine, HD-etoposide (R-HDS); BCNU-thiotepa-based conditioning and ASCT. Pts received 6 doses of i.v. rituximab and 4 doses of intrathecal liposomal cytarabine. Pts with CNS residual disease were referred to RT. The 2-year EFS is the primary endpoint (P0 40%; P1 60%; 38 pts required). This approach will be considered active if ≥21 pts will be progression free at 2 yrs. Results: the first 13 registered pts (median age 52 ys, 31-65; M/F ratio 1.6) were analyzed. Six pts were treated at diagnosis; 8 had systemic disease; no pt had positive CSF. Histotypes were diffuse large B-cell (10), mantle cell (2) and follicular (1) lymphomas. Bulky disease (1), ECOG-PS 2-3 (4) and B-symptoms (1) were uncommon; elevated LDH levels were observed in 10 pts. Treatment was completed in 8 pts, is ongoing in 3 (R-HDS), and was interrupted in 2: before conditioning in a poor mobilizer and after the first course due to PD. There were no toxic deaths. G4 neutropenia and thrombocytopenia were reported in all pts, febrile neutropenia in 7, other septic complications in 5. G3-4 non-hematological toxicity was not reported. PBSC collection was successful in 8 of the 9 referred pts (median 9.35 × 109/kg). Nine (69%) pts achieved a CR, 3 a PR (ORR 92%), 1 pt had PD. No pt received RT. At a median f-up of 15 m, 4 pts experienced relapse/PD (CNS 3, extra-CNS 1), with a 2-yr EFS of 46%; 9 pts are alive with a 2-yr OS of 54%. Conclusions: R-HDS supported by ASCT is feasible in pts ≤65 ys old with SCNSL. Preliminary results with this intensive approach are encouraging in this condition, with otherwise dismal prognosis. No significant financial relationships to disclose.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
狮子沟核聚变骡子完成签到 ,获得积分10
1秒前
Lu发布了新的文献求助10
2秒前
2秒前
3秒前
4秒前
4秒前
天才小熊猫完成签到,获得积分10
8秒前
李w完成签到,获得积分10
13秒前
13秒前
懂得珍惜发布了新的文献求助10
17秒前
冬枣枣发布了新的文献求助10
19秒前
qkl完成签到,获得积分20
20秒前
tjzbw完成签到,获得积分10
20秒前
22秒前
gonna完成签到,获得积分10
23秒前
Akim应助tanjuan采纳,获得10
23秒前
852应助人机灵采纳,获得10
23秒前
科研通AI5应助Martin采纳,获得10
25秒前
懂得珍惜完成签到,获得积分20
25秒前
kearthy完成签到,获得积分10
26秒前
qiqi发布了新的文献求助10
26秒前
26秒前
顾矜应助qkl采纳,获得10
26秒前
称心的士晋应助Robin采纳,获得10
27秒前
27秒前
桐桐应助范小楠采纳,获得10
28秒前
852应助妥妥酱采纳,获得10
29秒前
共享精神应助瓶子采纳,获得10
29秒前
逝者如斯只是看着完成签到,获得积分10
30秒前
楼亦玉完成签到,获得积分10
30秒前
30秒前
31秒前
小鞋发布了新的文献求助10
31秒前
CountFCL发布了新的文献求助10
31秒前
李振博完成签到 ,获得积分10
33秒前
35秒前
tanjuan发布了新的文献求助10
35秒前
塔图姆完成签到,获得积分10
39秒前
yangerbao发布了新的文献求助10
40秒前
Sssssss完成签到 ,获得积分10
43秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
England and the Discovery of America, 1481-1620 600
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3572505
求助须知:如何正确求助?哪些是违规求助? 3142644
关于积分的说明 9448520
捐赠科研通 2844063
什么是DOI,文献DOI怎么找? 1563224
邀请新用户注册赠送积分活动 731661
科研通“疑难数据库(出版商)”最低求助积分说明 718667